Please assess the completion status of the following clinical trial:

Trial Title: Safety of Liraglutide in Pediatric Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* BMI greater than 85th percentile for age and gender~* Currently being treated with diet and exercise or metformin alone~* HbA1c (glycosylated haemoglobin) between 6.5 and 11.0%~Exclusion Criteria:~* Any clinically significant disease other than type 2 diabetes, as judged by the trial physician~* Previous treatment with any anti-diabetic drug other than metformin (except for prior short term treatment, at the discretion of the trial physician)

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- I.a (Type: EXPERIMENTAL): None
- I.b (Type: PLACEBO_COMPARATOR): None
- II.a (Type: EXPERIMENTAL): None
- II.b (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).